Results 81 to 90 of about 15,288 (159)

Protein Lactylation in Cancer: Mechanisms and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 3, March 2026.
This schematic illustrates the central role of lactylation, a lactate‐derived posttranslational modification, in linking metabolic reprogramming to cancer progression and therapy resistance. At its core, lactylation modulates proteins, influenced by metabolic shifts and environmental factors.
Qianying Ouyang   +10 more
wiley   +1 more source

Advances and Prospects of Stereotactic Radiosurgery and Stereotactic Ablative Body Radiotherapy: Evolving Paradigms in Precision Oncology

open access: yesMed Research, Volume 2, Issue 1, Page 157-180, March 2026.
The graphical abstract outlines the progressive development and impact of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). Technological Evolution illustrates the transition from brachytherapy with single‐dose, LDR/HDR schedules to fractionated radiotherapy, three‐dimensional conformal radiotherapy (3DCRT) and Gamma Knife ...
Jing Zhang   +10 more
wiley   +1 more source

The Contribution of Cholesterol and Squalene Synthase in Cancer: Molecular Mechanisms, Lipid Rafts and Therapeutic Approaches

open access: yesMedicinal Research Reviews, Volume 46, Issue 2, Page 352-381, March 2026.
ABSTRACT A plethora of cellular signaling pathways are dysregulated in cancer cells, promoting carcinogenesis and migration. Cholesterol has recently been linked to cancer by several subcellular mechanisms, especially by its involvement in the formation of lipid rafts, which promote oncogenic signaling and cancer cell invasion. Squalene synthase (SQS),
Danai Mavridi   +2 more
wiley   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang   +7 more
wiley   +1 more source

Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
Molecular glue degraders (MGDs) constitute an emerging class of therapeutic agents poised to revolutionize the paradigm of targeted drug discovery. By reprogramming E3 ubiquitin ligases to degrade proteins of interest (POI) via a transient formation of a ternary complex mediated by protein–protein interactions, MGDs surpass the intrinsic limitations of
Jinfeng Wen   +3 more
wiley   +1 more source

The Role of One‐Carbon Metabolism in Cancer and Its Therapeutic Significance

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
One‐Carbon metabolism in T‐cell activation and tumor competition. T‐cell activation shifts metabolic pathways, promoting anabolic metabolism and bioenergetic capacity. One‐carbon metabolism plays a crucial role in histone and DNA methylation in activated T cells.
Yuting Jiang   +3 more
wiley   +1 more source

Cystoscopic ICG‐Guided Sentinel Lymph Node Dissection in Robotic Radical Prostatectomy: A Prospective Study

open access: yesThe Prostate, Volume 86, Issue 4, Page 481-492, March 2026.
ABSTRACT Background To evaluate the diagnostic accuracy, procedural feasibility, and clinical outcomes of a novel cystoscopic‐guided indocyanine green (ICG) injection technique followed by fluorescence‐guided sentinel lymph node dissection (SLND) during robotic‐assisted radical prostatectomy (RaRP), hereafter referred to as CysICG‐SLND.
Yi Hong Li   +7 more
wiley   +1 more source

IL-6/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities. [PDF]

open access: yesFront Immunol
Zhou T   +13 more
europepmc   +1 more source

RB1 inactivation in cutaneous carcinomas

open access: yesHistopathology, Volume 88, Issue 4, Page 769-789, March 2026.
Among skin carcinomas, recurrent RB1 inactivation is observed in Merkel cell carcinoma, in a subset of squamous cell carcinoma with bowenoid morphology, in sebaceous carcinoma and in the recently described Wnt/beta‐catenin rosette‐forming carcinoma.
Tiffany Liv   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy